Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study

Why did US jobless claims drop last week? How will Iran-Israel tensions affect global oil prices? What impact will Nippon Steel’s US Steel takeover have? Why is Amazon cutting corporate jobs with AI? How does Senate’s stablecoin bill affect crypto markets? Why is the US housing market slump worsening? What does Trump’s tax bill mean for businesses?

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study

benzinga.com/news/health-care/25/06/45998123/scholar-rocks-atrophy-drug-when-combined-with-eli-lillys-zepbound-shows-around-55-better-muscle-

Scholar Rock (NASDAQ:SRRK) revealed results on Wednesday from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced weight loss.
Tirzepatide is an active ingredient in Eli Lilly And Co’s…

This story appeared on benzinga.com, 2025-06-18 14:47:38.